In this week’s episode, Patrick is joined by Michelle Teng, CEO and Co-Founder of Etcembly Ltd and Founding Executive Director and Chief Scientific Officer of SynaptixBio. Michelle explains how her team is training large language models (LLMs) to analyze immune system data and how the company’s Long Term Survivor Study is helping identify T-cell profiles associated with sustained cancer remission. She also speaks to her own experience of ultra-rare genetic disease.
EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd. | The Genetics Podcast - Listen or read transcript on Metacast
